Summary: In a prespecified pooled secondary analysis of the STEP-HFpEF and STEP-HFpEF DM trials (1,145 randomized adults with obesity-related HFpEF; 71% with CRP at least 2 mg/L), once-weekly semaglutide 2.4 mg improved health status, body weight, and 6-minute walk distance consistently across all baseline C-reactive protein categories (all P interaction nonsignificant). Semaglutide also lowered CRP more than placebo regardless of baseline CRP (P interaction 0.32), and the reduction in CRP was independent of weight-loss magnitude (P interaction 0.91).
PICO Summary
| Element | Detail |
|---|---|
| Population | 1,145 randomized adults with obesity-related heart failure with preserved ejection fraction (HFpEF); pooled data from 2 international, double-blind, placebo-controlled randomized trials (STEP-HFpEF and STEP-HFpEF DM); 71% had baseline C-reactive protein (CRP) at least 2 mg/L. Patients stratified into 3 CRP categories (less than 2; 2 to less than 10; at least 10 mg/L). |
| Intervention | Once-weekly subcutaneous semaglutide 2.4 mg for 52 weeks. |
| Comparison | Matched placebo, once weekly for 52 weeks. |
| Outcome | Improvements in the dual primary endpoints (KCCQ-CSS health status and body weight), plus 6-minute walk distance and a hierarchical composite endpoint, were consistent across baseline CRP categories (all P interaction nonsignificant), indicating no effect modification by inflammation. Semaglutide reduced CRP more than placebo regardless of baseline CRP level (P interaction 0.32). Change in CRP from baseline to 52 weeks was similar regardless of the magnitude of weight loss (P interaction 0.91). As a subgroup-interaction analysis, no new treatment-effect estimates, 95% CIs, or NNT for the CRP strata are reported. |
Expert Commentary
This prespecified pooled secondary analysis is best read as a consistency and mechanism-probing exercise rather than as a fresh efficacy verdict. The headline is reassuring but modest: across patients with low, moderate, and high baseline inflammation, the clinical benefits of semaglutide on symptoms, weight, and exercise capacity were broadly similar, and CRP fell more with semaglutide than with placebo irrespective of how much weight was lost. The nonsignificant interaction terms support the absence of effect modification by inflammation, but they should not be overread; subgroup-interaction tests are typically underpowered, so failure to detect heterogeneity is weaker evidence than a demonstrated equivalence. The suggestion that semaglutide may dampen inflammation through pathways partly uncoupled from weight loss is hypothesis-generating, not established. The analysis carries clear manufacturer involvement: the trials were funded by Novo Nordisk, the maker of semaglutide, and several authors are company employees, which warrants the usual caution even within a double-blind design. Can I use this with my patients? Yes, in the sense that an obese patient with HFpEF who is a candidate for semaglutide should not be excluded on the basis of low or high CRP, since benefit appears consistent. It is not a reason to start semaglutide to treat inflammation per se. Confirmatory, hard-outcome data would strengthen this signal.
References
Verma S, Petrie MC, Borlaug BA, et al. Inflammation in Obesity-Related HFpEF: The STEP-HFpEF Program. J Am Coll Cardiol. 2024;84(17):1646-1662. doi:10.1016/j.jacc.2024.08.028